Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. RidgeMatthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

Research output: Contribution to journalArticle

89 Scopus citations

Abstract

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Original languageEnglish (US)
Pages (from-to)1671-1680
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., Lydiatt, W. M., McCaffrey, J., Moley, J. F., Parks, L., Raeburn, C. D., ... Hughes, M. (2014). Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(12), 1671-1680. https://doi.org/10.6004/jnccn.2014.0169